CMS Coverage, FDA Review Process Overlap Studied By HHS Secretary Panel
This article was originally published in The Gray Sheet
Executive Summary
The HHS Secretary's Advisory Committee on Regulatory Reform will consider proposals to coordinate CMS' coverage analysis process with FDA's evaluation of new technologies to prevent duplicative requirements
You may also be interested in...
Unique Missions Of FDA, CMS Underscored In Presentations To HHS Panel
Ongoing attempts to coordinate FDA and CMS reviews will preserve approval, coverage, coding and payment as distinct processes, agency representatives concurred at the HHS Secretary's Advisory Committee on Regulatory Reform regional hearing June 10
Feigal, Tunis To Present At HHS Reg Reform Panel On FDA/CMS Partnerships
Collaborative opportunities between FDA and the Centers for Medicare & Medicare Services for approving new technologies will be explored during the upcoming 1HHS Advisory Committee on Regulatory Reform's public hearing in Minneapolis
Feigal, Tunis To Present At HHS Reg Reform Panel On FDA/CMS Partnerships
Collaborative opportunities between FDA and the Centers for Medicare & Medicare Services for approving new technologies will be explored during the upcoming 1HHS Advisory Committee on Regulatory Reform's public hearing in Minneapolis